vs
牛津地产（IIPR）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
牛津地产的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$66.7M vs $35.5M），牛津地产净利率更高（47.8% vs -304.2%，领先352.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -13.1%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -6.0%）
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
IIPR vs RXRX — 直观对比
营收规模更大
IIPR
是对方的1.9倍
$35.5M
营收增速更快
RXRX
高出694.9%
-13.1%
净利率更高
IIPR
高出352.0%
-304.2%
两年增速更快
RXRX
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.7M | $35.5M |
| 净利润 | $31.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 47.8% | -304.8% |
| 净利率 | 47.8% | -304.2% |
| 营收同比 | -13.1% | 681.7% |
| 净利润同比 | -20.4% | 39.6% |
| 每股收益（稀释后） | $1.07 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IIPRRXRX
| Q4 25 | $66.7M | $35.5M | ||
| Q3 25 | $64.7M | $5.2M | ||
| Q2 25 | $62.9M | $19.2M | ||
| Q1 25 | $71.7M | $14.7M | ||
| Q4 24 | $76.7M | $4.5M | ||
| Q3 24 | $76.5M | $26.1M | ||
| Q2 24 | $79.8M | $14.4M | ||
| Q1 24 | $75.5M | $13.8M |
净利润IIPRRXRX
| Q4 25 | $31.8M | $-108.1M | ||
| Q3 25 | $29.3M | $-162.3M | ||
| Q2 25 | $26.0M | $-171.9M | ||
| Q1 25 | $31.1M | $-202.5M | ||
| Q4 24 | $40.0M | $-178.9M | ||
| Q3 24 | $40.2M | $-95.8M | ||
| Q2 24 | $42.0M | $-97.5M | ||
| Q1 24 | $39.4M | $-91.4M |
毛利率IIPRRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率IIPRRXRX
| Q4 25 | 47.8% | -304.8% | ||
| Q3 25 | 45.5% | -3327.6% | ||
| Q2 25 | 45.9% | -916.8% | ||
| Q1 25 | 47.4% | -1297.9% | ||
| Q4 24 | 54.7% | -4042.4% | ||
| Q3 24 | 54.8% | -377.1% | ||
| Q2 24 | 53.1% | -697.4% | ||
| Q1 24 | 55.7% | -698.4% |
净利率IIPRRXRX
| Q4 25 | 47.8% | -304.2% | ||
| Q3 25 | 45.3% | -3135.3% | ||
| Q2 25 | 41.4% | -894.2% | ||
| Q1 25 | 43.3% | -1373.3% | ||
| Q4 24 | 52.2% | -3935.5% | ||
| Q3 24 | 52.6% | -367.5% | ||
| Q2 24 | 52.6% | -676.6% | ||
| Q1 24 | 52.3% | -662.4% |
每股收益（稀释后）IIPRRXRX
| Q4 25 | $1.07 | $-0.17 | ||
| Q3 25 | $0.97 | $-0.36 | ||
| Q2 25 | $0.86 | $-0.41 | ||
| Q1 25 | $1.03 | $-0.50 | ||
| Q4 24 | $1.35 | $-0.56 | ||
| Q3 24 | $1.37 | $-0.34 | ||
| Q2 24 | $1.44 | $-0.40 | ||
| Q1 24 | $1.36 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.6M | $743.3M |
| 总债务越低越好 | $393.7M | $9.6M |
| 股东权益账面价值 | $1.8B | $1.1B |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.21× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资IIPRRXRX
| Q4 25 | $47.6M | $743.3M | ||
| Q3 25 | $41.9M | $659.8M | ||
| Q2 25 | $104.9M | $525.1M | ||
| Q1 25 | $133.3M | $500.5M | ||
| Q4 24 | $151.2M | $594.4M | ||
| Q3 24 | $172.4M | $427.6M | ||
| Q2 24 | $160.9M | $474.3M | ||
| Q1 24 | $173.5M | $296.3M |
总债务IIPRRXRX
| Q4 25 | $393.7M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益IIPRRXRX
| Q4 25 | $1.8B | $1.1B | ||
| Q3 25 | $1.9B | $1.0B | ||
| Q2 25 | $1.9B | $919.1M | ||
| Q1 25 | $1.9B | $933.9M | ||
| Q4 24 | $1.9B | $1.0B | ||
| Q3 24 | $1.9B | $524.6M | ||
| Q2 24 | $1.9B | $584.4M | ||
| Q1 24 | $2.0B | $401.2M |
总资产IIPRRXRX
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.3B | $1.4B | ||
| Q2 25 | $2.3B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.4B | ||
| Q3 24 | $2.4B | $726.5M | ||
| Q2 24 | $2.4B | $775.9M | ||
| Q1 24 | $2.4B | $557.8M |
负债/权益比IIPRRXRX
| Q4 25 | 0.21× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.2M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 6.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流IIPRRXRX
| Q4 25 | $198.2M | $-46.1M | ||
| Q3 25 | $45.6M | $-117.4M | ||
| Q2 25 | $48.4M | $-76.4M | ||
| Q1 25 | $54.2M | $-132.0M | ||
| Q4 24 | $258.4M | $-115.4M | ||
| Q3 24 | $64.9M | $-59.2M | ||
| Q2 24 | $64.2M | $-82.2M | ||
| Q1 24 | $71.6M | $-102.3M |
自由现金流IIPRRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率IIPRRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度IIPRRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率IIPRRXRX
| Q4 25 | 6.22× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 6.46× | — | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
